See the 27-slide presentation a secretive biotech startup backed by Sean Parker used to raise $40 million and 'open a new universe' in cancer immunotherapy
Summary
3T shared its 27-slide investor deck that describes its technology platform.More than five years after its founding, a secretive biotech startup backed by the billionaires Sean Parker and Peter Thiel publicly launched Thursday, sharing details on its unique approach to cancer research.South San Francisco, California-based 3T Biosciences announced a $40 million Series A round led by Westlake Village BioPartners and a new leadership team focused on bringing the startups technology into human testing.3Ts cancer research is working on identifying proteins found inside cancerous cells and then using those proteins to help immune cells hunt and destroy tumors.Two industry veterans are now leading 3T. Stefan Scherer has been CEO since July 2021 brings more than two decades of industry experience at Roche, Novartis, GSK and other drugmakers. The field has seen remarkable success, particularly with the first cell therapy programs now approved treatments effectively curing certain types of blood cancer.But the approach has struggled against solid tumors, which are more common.A key issue is the lack of new targets. "Solving that question has led 3T on a long, winding road: building a technology platform complete with massive datasets, machine learning, and intricate drug design research to create potential treatments.Despite the promise, it will take years to see if 3Ts approach can be successful. The company plans to file to start human testing of its first experimental cancer therapy in 2023 or early 2024, Scherer said.Parkers cancer-research institute supported the Series A round, while Thiel did not participate, Harper said.